NanoViricides, Inc. (NYSE American: NNVC), a clinical-stage antiviral drug developer, has reported progress in its Phase IIA clinical trial of NV-387 Oral Gummies for the treatment of Ebola Bundibugyo virus disease in the Democratic Republic of Congo (DRC). The company anticipates advancing to Phase IIB following completion of the initial study phase. Enrollment began on September 23, 2026, with approximately 20 patients expected to participate in Phase IIA, which is designed to evaluate dosing regimens based on disease severity. The primary endpoint is 28-day survival, and the initial phase will conclude once the final enrolled patient completes the observation period.
The announcement holds significant implications because the ongoing Ebola Bundibugyo outbreak in the DRC has resulted in more than 10,000 confirmed cases and approximately 4,900 deaths. Currently, no treatments or vaccines are approved specifically for Ebola Bundibugyo, and according to NanoViricides, NV-387 Oral Gummies is the only oral drug candidate undergoing clinical evaluation for the disease. An oral antiviral could be particularly valuable in outbreak settings where healthcare infrastructure is limited, as it may be easier to administer than injectable therapies. The company is also evaluating NV-387 Oral Gummies in a separate Phase II clinical trial for mpox in the DRC, further exploring the drug's potential across multiple viral diseases. For a detailed view of the progress, the full press release is available at https://ibn.fm/JJ69W.
NanoViricides is a clinical-stage company creating special purpose nanomaterials for antiviral therapy. Its novel nanoviricide class of drug candidates and technology are based on intellectual property, technology, and proprietary know-how of TheraCour Pharma, Inc. The company's lead drug candidate, NV-387, is a broad-spectrum antiviral being developed for RSV, COVID, Long COVID, Influenza, and other respiratory viral infections, as well as MPOX/Smallpox and Measles. Another advanced candidate is NV-HHV-1 for the treatment of Shingles. The company's business model is based on licensing technology from TheraCour Pharma for specific application verticals of specific viruses. More information about the company can be found at www.nanoviricides.com.
The latest news and updates relating to NNVC are available in the company's newsroom at https://ibn.fm/NNVC. The announcement was distributed through BioMedWire, a specialized communications platform focused on the Biotechnology, Biomedical Sciences, and Life Sciences sectors. BioMedWire is part of the Dynamic Brand Portfolio at IBN, which provides wire solutions via InvestorWire, editorial syndication to 5,000+ outlets, press release enhancement, social media distribution, and corporate communications solutions. For more information, visit BioMedWire.
